BeiGene, Ltd. announced that the FDA has approved Tevimbra (tislelizumab-jsgr) as monotherapy for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor . Tevimbra will be available in the U.S. in the second half of 2024.
FibroGen, Inc. announced that roxadustat, an inhibitor of hypoxia-inducible-factor (HIF) prolyl hydroxylase activity (HIF-PHI), met all primary efficacy endpoints in...
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. have announced that the FDA has approved Sucampo�s supplemental new drug application...